Himmatrao Saluba Bawaskar
Himmatrao Saluba Bawaskar
María Romay Barja,Ivana Brkic Bilos,Eugenia Claudia Bratu et al.
María Romay Barja et al.
Lindsay Stark,Chen Reis,Ilana Seff et al.
Lindsay Stark et al.
Michele Ghidini,Gianluca Tomasello
Michele Ghidini
The Lancet
The Lancet
To be a distant witness [0.03%]
做一名遥远的目击者
Mandip Aujla
Mandip Aujla
The Pandemic Agreement is a milestone: now it is time for action in national capitals [0.03%]
大流行病疫苗全球获取机制是里程碑式的成就 领导人须在国内兑现承诺
Helen Clark,Ellen Johnson Sirleaf
Helen Clark
Sudan's tuberculosis response needs global support amid conflict [0.03%]
苏丹的结核病应对措施需要全球支持新冠疫情下冲突地区医疗系统承压
Ahmad Mohammad Al Zamel,Ali Awadallah Saeed,Mazin Elmubarak et al.
Ahmad Mohammad Al Zamel et al.
Efficacy and safety of selumetinib in adults with neurofibromatosis type 1 and symptomatic, inoperable plexiform neurofibromas (KOMET): a multicentre, international, randomised, placebo-controlled, parallel, double-blind, phase 3 study [0.03%]
Selumetinib治疗1型神经纤维瘤病成人患者的疗效和安全性：一项国际多中心、随机、双盲、安慰剂对照的平行分组III期临床研究（KOMET）
Alice P Chen,Geraldine O&#x;Sullivan Coyne,Pamela L Wolters et al.
Alice P Chen et al.
Background: Currently, no worldwide approved therapies exist for adults with neurofibromatosis type 1 (NF1) and symptomatic, inoperable plexiform neurofibromas. The KOMET study aimed to evaluate selumetinib (ARRY-142886, ...